 |
|
|
| |
Identification and Treatment of Multiple Subtypes of HCV Genotype 4 in the PEARL-I Study With Ombitasvir and ABT-450/r ± Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD Nov 7-11 Boston
Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Preethi Krishnan, Tolga Baykal, Coleen Hall, Regis A Vilchez, Tami Pilot-Matias, and Christine Collins
Research & Development, AbbVie Inc., North Chicago, Illinois, United States
AASLD: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results - (12/01/14)
|
| |
|
|
|
|
|
